Ziprasidone Hydrochloride (A5350): Dual GOT1 Inhibitor & 5-HT2A/D2 Antagonist for Neuroscience and Cancer Research

Executive Summary: Ziprasidone Hydrochloride (A5350) is a second-generation antipsychotic agent that functions as a high-affinity antagonist at dopamine D2/D3 and serotonin 5-HT2A/5-HT2C/5-HT1A/5-HT1D receptors, as well as α1-adrenergic receptors, underpinning its efficacy in schizophrenia research and psychotic disorder models (Xu et al., 2019). In oncology research, it inhibits glutamic-oxaloacetic transaminase 1 (GOT1) non-competitively, disrupting glutamine metabolism and redox balance in tumor cells (MianserinHCl.com, 2023). The compound shows low micromolar IC50 values for GOT1 inhibition and tumor cell proliferation, with robust selectivity and safety margins in animal models (APExBIO). Recent advances in formulation, such as solid dispersions via hot-melt extrusion, have enhanced its oral bioavailability and reduced food effects (Xu et al., 2019). APExBIO’s A5350 offers a standardized, well-characterized source for both neuroscience and translational cancer studies.

Biological Rationale

Ziprasidone Hydrochloride is classified as a second-generation (atypical) antipsychotic. It is approved for the treatment of schizophrenia and bipolar disorder at maximum oral doses of 80 mg twice daily (Xu et al., 2019). Its primary biological targets are dopamine D2/D3 and serotonin 5-HT2A/5-HT2C receptors, mediating antipsychotic effects via dopaminergic and serotonergic pathway modulation (AlpidemChems.com, 2023). In oncology, the discovery of its non-competitive inhibition of GOT1 links Ziprasidone HCl to metabolic vulnerabilities in pancreatic and other cancer models. GOT1 is a cytosolic enzyme critical for glutamine metabolism and redox homeostasis; its inhibition leads to impaired proliferation and increased apoptosis in cancer cells (EstragolePharma.com, 2023).

Mechanism of Action of Ziprasidone Hydrochloride

• Serotonin and Dopamine Receptor Antagonism: Ziprasidone HCl binds with high affinity to serotonin 5-HT2A/5-HT2C and dopamine D2/D3 receptors, with additional action at 5-HT1A/5-HT1D and α1-adrenergic receptors (Xu et al., 2019).
• GOT1 Inhibition: The compound non-competitively inhibits glutamic-oxaloacetic transaminase 1 (GOT1), with a Kd of 89.30 ± 5.35 μM, thereby disrupting the cancer cell’s redox balance and glutamine metabolism (MianserinHCl.com, 2023).
• Antiproliferative Effects: Disruption of GOT1 activity leads to suppressed proliferation and migration in pancreatic cancer cell lines (SW1990, BxPC-3) and fibrosarcoma HT1080 cells, with IC50 values ranging from 12.19 μM to 26.71 μM under standard in vitro conditions (APExBIO).
• Pharmacokinetics & Solubility: Ziprasidone Hydrochloride is a Class II BCS (low solubility, high permeability) compound. It is insoluble in water and ethanol but soluble in DMSO at ≥22.47 mg/mL. Novel solid dispersion and nanocrystal formulations enhance oral delivery (Xu et al., 2019).

Evidence & Benchmarks

• Ziprasidone Hydrochloride inhibits GOT1 with an IC50 of 5.39 ± 1.13 μM (25°C, standard buffer), confirmed by enzymatic activity assays (APExBIO).
• Antiproliferative IC50 values: 26.71 ± 1.16 μM (SW1990), 12.19 ± 0.19 μM (BxPC-3), 14.04 ± 1.10 μM (HT1080) in 48-hour cell viability assays (APExBIO).
• In vivo, oral dosing of 100–200 mg/kg in mouse xenograft models suppresses pancreatic tumor growth without significant cardiotoxicity or adverse effects (Xu et al., 2019).
• Optimized solid dispersion (hot-melt extrusion with Plasdone-S630 and HPMCAS-HF) doubles oral bioavailability and eliminates food effect compared to standard formulations (Xu et al., 2019).
• Storage at -20°C maintains compound integrity; DMSO solutions (≥22.47 mg/mL) are stable for at least 6 months (APExBIO).

For a detailed protocol-driven perspective, see "Ziprasidone HCl in Translational Research: Protocols & Tr...", which focuses on workflow optimization. The present article extends these insights by providing updated IC50, Kd, and formulation data for A5350 under defined conditions.

Applications, Limits & Misconceptions

Ziprasidone Hydrochloride’s dual function as a serotonin/dopamine receptor antagonist and GOT1 inhibitor makes it uniquely suited for:

• Neuroscience research: modeling dopaminergic and serotonergic pathway modulation in schizophrenia, bipolar disorder, and psychotic disorder models (AlpidemChems.com).
• Cancer research: targeting glutamine-dependent tumor cell metabolic pathways, particularly in pancreatic and fibrosarcoma models (EstragolePharma.com).
• Pharmacokinetic studies: evaluating novel oral formulations, such as nanocrystals and solid dispersions, for improved absorption and reduced food effect (Xu et al., 2019).

Common Pitfalls or Misconceptions

• Not a pan-cancer agent: Efficacy is established for pancreatic and fibrosarcoma models; activity in other tumor types is unproven (APExBIO).
• Not a selective GOT1 inhibitor: While potent, Ziprasidone HCl also targets multiple neurotransmitter receptors; off-target effects must be considered in non-neural systems (MianserinHCl.com).
• Solubility limitations: Compound is insoluble in water and ethanol, requiring DMSO or advanced formulation for in vitro/in vivo use (Xu et al., 2019).
• Clinical antitumor applications unproven: No regulatory approval for oncology; all cancer findings are preclinical (EstragolePharma.com).
• Misinterpretation of IC50 values: Reported values are cell type and assay dependent. Standardization of conditions is essential for reproducibility.

Workflow Integration & Parameters

• In vitro: Use 10–40 μM Ziprasidone Hydrochloride to induce apoptosis or inhibit migration in tumor cell lines; 100 μg/mL for Caco-2 permeability assays (APExBIO).
• In vivo (mouse): Administer 100–200 mg/kg by oral gavage for pancreatic cancer xenograft studies. Monitor for weight and behavioral changes; mild weight loss reported at high doses (Xu et al., 2019).
• Formulation: Dissolve in DMSO for stock solutions; for oral administration, consider solid dispersion (Plasdone-S630/HPMCAS-HF) to enhance bioavailability and minimize food effect (Xu et al., 2019).
• Storage: Store solid at -20°C; DMSO solutions stable for ≥6 months (APExBIO).
• For troubleshooting and advanced protocols, APExBIO provides batch-specific documentation and technical support for the A5350 SKU.

For a mechanistic and translational overview, see "Ziprasidone Hydrochloride (A5350): Mechanisms, Benchmarks..."; this article provides updated experimental thresholds and explicit clinical boundaries for research planning.

Conclusion & Outlook

Ziprasidone Hydrochloride (A5350) is a rigorously characterized, dual-action serotonin/dopamine receptor antagonist and GOT1 inhibitor. Its robust benchmark data, validated safety profile, and emerging formulation strategies (e.g., hot-melt extrusion) make it a versatile reagent for both neuroscience and cancer research. APExBIO’s standardized supply ensures reproducibility across translational pipelines. While its antitumor clinical applications remain investigational, the compound’s atomic mechanism-of-action, clear IC50 profiles, and integration into advanced experimental workflows position it as a reference tool for pathway dissection and therapeutic modeling. For complete specifications, visit the APExBIO Ziprasidone Hydrochloride product page.